Testosterone Cypionate and Erythrocytosis: The Biology of Why Hematocrit Rises

What does erythrocytosis mean on testosterone cypionate?

Erythrocytosis is an increase in red blood cell mass, reflected by higher hemoglobin and hematocrit. Testosterone products raise both, and the Depo-Testosterone label lists polycythemia as a hematologic adverse reaction [1]. Studies use different cutoffs: a retrospective review defined erythrocytosis as hematocrit above 50% [4], while a review of aging men used hematocrit above 0.52, or 52% [6]. That difference matters when comparing rates across studies.

Which biological signals explain the rise?

The Depo-Testosterone label states that androgens stimulate red blood cell production by enhancing production of an erythropoietic stimulation factor [1]. The label makes this statement for androgens as a class.

The most detailed human data come from a 6-month randomized trial of daily testosterone gel in older men with mobility limitation, not testosterone cypionate injections. In that trial, the increase was about 7% for hemoglobin and about 10% for hematocrit [2]. The rise was associated with significantly increased erythropoietin and decreased ferritin and hepcidin at 1 and 3 months [2]. Soluble transferrin receptor and the ratio of soluble transferrin receptor to log ferritin rose, consistent with increased iron use for red-cell production [2].

At 6 months, erythropoietin and hepcidin moved back toward baseline despite continued testosterone, but erythropoietin remained nonsuppressed while hemoglobin and hematocrit stayed above baseline [2]. The authors proposed that testosterone recalibrates the erythropoietin set point in relation to hemoglobin and increases iron use for red-cell production [2].

A 2018 review of testosterone erythrocytosis lists hepcidin, iron sequestration and turnover, erythropoietin production, bone marrow stimulation, and genetic factors as proposed mechanisms [7]. The review calls these potential mechanisms [7].

Do injections raise hematocrit more than gels?

Route matters in the data. A 2022 network meta-analysis of 29 placebo-controlled randomized trials in 3,393 men found that every testosterone formulation raised mean hematocrit compared with placebo [3]. Intramuscular testosterone enanthate or cypionate produced a mean hematocrit rise of 4.0% (95% CI 2.9 to 5.1), gel 3.0% (1.8 to 4.3), patch 1.4% (0.2 to 2.6), oral testosterone undecanoate 4.3% (0.7 to 8.0), and intramuscular testosterone undecanoate 1.6% (0.3 to 3.0) [3]. In that analysis, intramuscular enanthate or cypionate raised hematocrit significantly more than patch; the other pairwise comparisons were not significantly different [3].

Observational data point the same way but are weaker. A retrospective review of 178 hypogonadal men followed for 3 years found hematocrit above 50% in 66.7% of men on injectable testosterone, 12.8% on gels, and 35.1% on pellets [4]. The injection group was younger, with a mean age of 42.5 years versus 54.1 on gel and 53.8 on pellets, and started with higher free testosterone, hemoglobin, and hematocrit [4]. The study was not randomized [4].

The 2018 review reports that short-acting injectable formulations have the highest associated incidence of erythrocytosis [7]. A 2025 systematic review of drug-induced erythrocytosis found rates up to 66.7% with prescription testosterone and associated intramuscular formulations, higher doses, and older age with increased risk [8].

Does dose change the hematocrit response?

A randomized dose-response trial in 61 healthy young men suppressed their own testosterone with a GnRH agonist and gave weekly testosterone enanthate injections of 25 to 600 mg for 20 weeks [9]. Hemoglobin changes were positively correlated with circulating testosterone concentration [9]. The 2025 systematic review also associated higher testosterone doses with more erythrocytosis [8]. The label dosing for Depo-Testosterone is 50 to 400 mg every 2 to 4 weeks for hypogonadal men [1].

How high can hematocrit go, and what do labels say?

The Depo-Testosterone label calls for periodic hemoglobin and hematocrit checks in long-term use and lists polycythemia as an adverse reaction [1].

The 2018 Endocrine Society guideline recommends against starting testosterone therapy in men with elevated hematocrit and recommends monitoring hematocrit in the first year of therapy [5]. A 2023 clinical consultation guide in European Urology Focus states that providers should decrease or discontinue therapy if hematocrit exceeds 54% until it normalizes [10].

Does erythrocytosis raise clot risk?

The Depo-Testosterone label lists venous thromboembolism among adverse reactions [1], but the 2018 review found limited evidence supporting a relationship between erythrocytosis and thromboembolic events [7]. A 2025 systematic review of drug-induced erythrocytosis reported thromboembolic events in up to 2.7% of men on testosterone therapy [8]. The 2018 review also says high blood viscosity increases the risk of potential vascular complications [7].

Is this the same as polycythemia vera?

Testosterone is a recognized cause of secondary erythrocytosis [8]. Polycythemia vera is a different condition. A hematology review says the first step in evaluating erythrocytosis is excluding polycythemia vera with JAK2 mutation screening of exons 12 to 15 [11].